Research
Hormonal
GLP-1 Receptor Agonists (GLP-1 RA) and SGLT-2 Inhibitors (SGLT-2i) provide significant cardiovascular and renal benefits, with GLP-1 RAs also offering substantial weight loss and HbA1c reduction.
Consider GLP-1 RAs or SGLT-2 inhibitors if you need better blood sugar control, weight loss, or heart protection. These drugs have strong evidence for reducing heart attacks and strokes. Be aware of potential stomach issues, which often improve over time.
StrongSupportsVERY_HIGH confidence
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer notable benefits for HbA1c and weight reduction, with significant cardiovascular benefits. Sodium-glucose cotransporter inhibitors (SGLT-2i) lower glucose levels independently of insulin while conferring notable benefits for cardiovascular, renal, and heart-failure outcomes.
Why this rating
Supported by multiple large-scale clinical trials (SELECT, SAVOR, EMPA-REG, etc.) and meta-analyses.
Source
Drug Therapies for Diabetes
Roni Weinberg Sibony et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms242417147
narrative_reviewCited 97×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin is the primary first-line oral treatment for type 2 diabetes across all age groups due to its efficacy, versatility, and cost-effectiveness, with benefits extending to cardiovascular and potential anti-neoplastic properties.Good
- Sulfonylureas are associated with weight gain, hypoglycemia, and declining long-term efficacy, making them unsuitable as first- or second-line treatments.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →